Pharmaceutical Technology15 時間
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
clinicaltrialsarena16 時間
MSD commences Phase III trial of DLBCL treatment
MSD has commenced the Phase III trial to assess zilovertamab vedotin combined with R-CHP to treat individuals with previously ...
Targeted Oncology1 日
FDA Grants Key Oncology Approvals and Designations in January 2025
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Cure Today2 日
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...
EuropaWire3 日
AstraZeneca’s Imfinzi Recommended for EU Approval as Breakthrough Treatment for Limited ...
AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...
oncnursingnews4 日
Oncology Drugs Approved by the FDA in January 2025
January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.
Cure Today4 日
Breaking Down Cancer Therapies Approved by the FDA in January 2025
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...